Announcements Trials
Browse Landscape

Phase

Phase 1 24Phase 1/2 16Phase 2 11Phase 4 2Phase 3 2Phase NA 1Phase EARLY_PHASE1 1Phase 2/3 1

Status

Unknown 1

Sponsor Class

OTHER 13INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Gastrointestinal 1CNS 1

Conditions

Multiple Myeloma 19Solid Tumor 18Breast Neoplasms 14Sarcoma 13Head and Neck Neoplasms 13Colorectal Neoplasms 13Neoplasms 12Lymphoma, B-Cell 12Squamous Cell Carcinoma of Head and Neck 11Pancreatic Neoplasms 11Leukemia, Myeloid, Acute 11Stomach Neoplasms 10Melanoma 10Lymphoma 9Carcinoma, Non-Small-Cell Lung 9Lung Neoplasms 8Prostatic Neoplasms 7Leukemia 7Burkitt Lymphoma 7Advanced Solid Tumors 7Ovarian Neoplasms 6Hematologic Neoplasms 6Glioblastoma 6Recurrence 5Osteosarcoma 5Lymphoma, Non-Hodgkin 5Carcinoma, Hepatocellular 5Triple Negative Breast Neoplasms 4Small Cell Lung Carcinoma 4Neoplasm Metastasis 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × INDUSTRY × Neuroblastoma × Clear all
NCT04864821 2021-05-06

Clinical Study of CD276 Targeted Autologous Chimeric Antigen Receptor T Cell Infusion in Patients With CD276 Positive Advanced Solid Tumor

PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Phase EARLY_PHASE1 Unknown
24 enrolled
CNSGastrointestinalSarcomaThoracic

Lung Neoplasms, Neuroblastoma, Osteosarcoma, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡